JAC Advance Access published online on September 12, 2003
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkg425
© 2003 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original article
1 The University of Texas
Health Science Center at San Antonio, Department of Medicine, Division
of Infectious Diseases (7881), 7703 Floyd Curl Drive, San Antonio,
TX 78229-3900, USA
* Corresponding author. E-mail: najvar{at}uthscsa.edu.
Received 6 March 2003
; revised 9 July 2003
; accepted 18 July 2003
Objectives: AmBisome and micafungin
were used alone and in combination in a series of studies designed to
identify any additive or antagonistic effects of combination antifungal
therapy. Methods: Immune-suppressed mice were infected
either intravenously or intranasally with Aspergillus fumigatus.
Micafungin, liposomal amphotericin B or both drugs together were
administered for 7 days. Parameters of efficacy included survival
and tissue burden of A. fumigatus. Results: Whilst each drug was effective in murine
aspergillosis, additive effects were observed only in reduction
of tissue burden in limited experimental conditions. No antagonism
was seen. Conclusions: The present studies neither encourage
nor discourage clinical use of combination therapy. Clinical trials
are suggested before combined therapy is routinely adopted.
Keywords: antifungals, Aspergillus fumigatus,
invasive aspergillosis
Combination antifungal therapy of murine aspergillosis:
liposomal amphotericin B and micafungin
2 The University of Texas
Health Science Center at San Antonio, Department of Medicine, Division
of Infectious Diseases (7881), 7703 Floyd Curl Drive, San Antonio,
TX 78229-3900, USA; Departamento
de Microbiología, Facultad de Medicina, Universidad Autónoma
de Nuevo León, Monterrey, N. L., Mexico
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Spreghini, F. Orlando, A. Santinelli, E. Pisa, C. Loretelli, E. Manso, M. E. Milici, G. Scalise, and F. Barchiesi Anidulafungin in Combination with Amphotericin B against Aspergillus fumigatus Antimicrob. Agents Chemother., September 1, 2009; 53(9): 4035 - 4039. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Nagasaki, Y. Eriguchi, Y. Uchida, N. Miyake, Y. Maehara, M. Kadowaki, M. Harada, K. Akashi, and N. Shimono Combination therapy with micafungin and amphotericin B for invasive pulmonary aspergillosis in an immunocompromised mouse model J. Antimicrob. Chemother., August 1, 2009; 64(2): 379 - 382. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Takazono, K. Izumikawa, T. Mihara, K. Kosai, T. Saijo, Y. Imamura, T. Miyazaki, M. Seki, H. Kakeya, Y. Yamamoto, et al. Efficacy of Combination Antifungal Therapy with Intraperitoneally Administered Micafungin and Aerosolized Liposomal Amphotericin B against Murine Invasive Pulmonary Aspergillosis Antimicrob. Agents Chemother., August 1, 2009; 53(8): 3508 - 3510. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O.S. Zmeili and A.O. Soubani Pulmonary aspergillosis: a clinical update QJM, June 1, 2007; 100(6): 317 - 334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hachem, P. Bahna, H. Hanna, L. C. Stephens, and I. Raad EDTA as an adjunct antifungal agent for invasive pulmonary aspergillosis in a rodent model. Antimicrob. Agents Chemother., May 1, 2006; 50(5): 1823 - 1827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. H. Segal and T. J. Walsh Current Approaches to Diagnosis and Treatment of Invasive Aspergillosis Am. J. Respir. Crit. Care Med., April 1, 2006; 173(7): 707 - 717. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Dennis, W. R. Greco, Y. Brun, R. Youn, H. K. Slocum, R. J. Bernacki, R. Lewis, N. Wiederhold, S. M. Holland, R. Petraitiene, et al. Effect of Amphotericin B and Micafungin Combination on Survival, Histopathology, and Fungal Burden in Experimental Aspergillosis in the p47phox-/- Mouse Model of Chronic Granulomatous Disease Antimicrob. Agents Chemother., February 1, 2006; 50(2): 422 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. V. Clemons, M. Espiritu, R. Parmar, and D. A. Stevens Comparative Efficacies of Conventional Amphotericin B, Liposomal Amphotericin B (AmBisome), Caspofungin, Micafungin, and Voriconazole Alone and in Combination against Experimental Murine Central Nervous System Aspergillosis Antimicrob. Agents Chemother., December 1, 2005; 49(12): 4867 - 4875. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Olson, J. P. Adler-Moore, P. J. Smith, and R. T. Proffitt Treatment of Candida glabrata Infection in Immunosuppressed Mice by Using a Combination of Liposomal Amphotericin B with Caspofungin or Micafungin Antimicrob. Agents Chemother., December 1, 2005; 49(12): 4895 - 4902. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Singh and D. L. Paterson Aspergillus Infections in Transplant Recipients Clin. Microbiol. Rev., January 1, 2005; 18(1): 44 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cuenca-Estrella Combinations of antifungal agents in therapy-what value are they? J. Antimicrob. Chemother., November 1, 2004; 54(5): 854 - 869. [Abstract] [Full Text] [PDF]
|
|